Hepatitis B Foundation

HEP B UNITED: A NATIONAL COALITION TO IMPROVE HEPATITIS B EDUCATION, AWARENESS, TESTING AND LINKAGE TO CARE AMONG HIGHLY IMPACTED COMMUNITIES - THE HEPATITIS B FOUNDATION (HBF) IN COLLABORATION WITH THE ASSOCIATION OF ASIAN PACIFIC COMMUNITY HEALTH ORGANIZATIONS (AAPCHO) WILL LEAD, MAINTAIN, AND GROW HEP B UNITED (HBU), A NATIONAL COALITION TO IMPROVE VIRAL HEPATITIS AWARENESS, TESTING AND LINKAGE TO CARE, AND ADDRESS THE HEALTH DISPARITIES ASSOCIATED WITH HEPATITIS B AMONG PRIORITY COMMUNITIES. HBF WILL BUILD THE CAPACITY OF COMMUNITY COALITIONS, COMMUNITY-BASED HEALTH CENTERS AND PUBLIC HEALTH DEPARTMENTS TO INCREASE VIRAL HEPATITIS EDUCATION AND TESTING AND IMPROVE LINKAGE TO CARE IN A CULTURALLY AND LINGUISTICALLY RESPONSIVE MANNER FOR COMMUNITIES DISPARATELY IMPACTED, INCLUDING ASIAN AMERICANS, NATIVE HAWAIIANS AND PACIFIC ISLANDERS (AANHPIS), AFRICAN IMMIGRANTS, AND PERSONS WHO INJECT DRUGS (PWIDS). WE WILL ALSO IMPROVE AWARENESS, DISSEMINATION OF USAGE OF THE CDC KNOW HEPATITIS B CAMPAIGN, AS A STRATEGY TO IMPROVE HEPATITIS B AWARENESS AND TESTING. HBU IS COMPRISED OF LOCAL COMMUNITY COALITIONS IN 22 STATES, 30 CITIES AND WASHINGTON, D.C. SINCE 2012, HBU HAS PROMOTED CROSS-SECTOR PARTNERSHIPS BETWEEN COMMUNITY ORGANIZATIONS, HEALTH DEPARTMENTS, AND FEDERALLY QUALIFIED HEALTH CENTERS (FQHCS), AND HAS BEEN BUILDING THE CAPACITY OF MULTISECTORAL COMMUNITY COALITIONS TO ADDRESS HEPATITIS B IN A NATIONALLY COORDINATED MANNER. THROUGH A HEALTH EQUITY LENS, HBF WILL BUILD AND STRENGTHEN THE HBU NETWORK AND OFFER CAPACITY BUILDING, TRAINING, TECHNICAL ASSISTANCE, AND NETWORKING. HBF?S PROGRAM STRATEGIES WILL INCLUDE: 1) MINI-GRANTS TO SUPPORT BEST PRACTICES IN HEPATITIS AWARENESS, EDUCATION, TESTING, AND LINKAGE TO CARE; 2) PEER MENTORING TO FOSTER THE DEVELOPMENT OF LOCAL AND/OR STATE HEPATITIS COMMUNITY COALITIONS AND ADDRESS SPECIFIC CAPACITY BUILDING NEEDS; 3) HEPATITIS B COMMUNITY HEALTH EDUCATION PROGRAM USING AN INTERACTIVE CASE-STUDIES APPROACH TO PROMOTE HEPATITIS PREVENTION AND CONTROL STRATEGIES; 4) HEPATITIS B COMMUNITY HEALTH CENTER LEARNING COLLABORATIVE TO FOSTER A COHORT OF NEW FQHCS SERVING AANHPIS, AFRICAN IMMIGRANTS, AND PWIDS TO PARTNER WITH COMMUNITY COALITIONS AND INTEGRATE AND IMPROVE THEIR CAPACITY TO IMPLEMENT HEPATITIS B EDUCATION, TESTING, AND LINKAGE TO CARE PROGRAMS; 5) HEP B UNITED COMMUNITY COALITION LEADERSHIP DEVELOPMENT PROGRAM TO IMPROVE THE CAPACITY OF INDIVIDUAL LOCAL COMMUNITY LEADERS TO LEAD AND GROW COMMUNITY-BASED HEPATITIS COALITIONS; 6) MONTHLY WEBINARS; 7) ANNUAL HEP B UNITED SUMMIT; 8) MONTHLY COALITION CALLS; AND 9) HEP B UNITED PACIFIC ISLANDER COMMUNITY AND HARM REDUCTION STRATEGY WORKGROUPS TO ADDRESS THE HIGH RATES OF CHRONIC HEPATITIS B AMONG PACIFIC ISLANDER COMMUNITIES AND PWIDS, RESPECTIVELY.

HEP B UNITED: MULTI-STATE NETWORKING, CAPACITY BUILDING AND TRAINING FOR INCREASED IDENTIFICATION OF CHRONIC HEPATITIS B INFECTIONS IN THE U.S.

HEP B UNITED: NETWORKING, CAPACITY BLDG & TRNG

THE EXPERIENCES OF ETHNIC MINORITIES, AND THOSE WITH LIVER DISEASE, DURING COVID-19, AND THE IMPACT ON RELATED HEALTH AND PREVENTION BEHAVIORS - THE EXPERIENCES OF ETHNIC MINORITIES, AND THOSE WITH LIVER DISEASE, DURING COVID-19, AND THE IMPACT ON RELATED HEALTH AND PREVENTION BEHAVIORS CHRONIC HEPATITIS B (CHB) INFECTION AFFECTS UP TO 2.4 MILLION PEOPLE LIVING IN THE U.S., AND DISPROPORTIONATELY IMPACTS PEOPLE OF ASIAN AND AFRICAN ORIGIN AND PACIFIC ISLANDERS, WHO ALSO FACE MANY CHALLENGES TO HEALTHCARE ACCESS. PEOPLE LIVING WITH HEPATITIS B (PLHB) WHO REPRESENT ETHNIC MINORITIES ALSO LACK ACCESS TO CLINICAL TRIALS; DELAYING THEIR EQUITABLE ACCESS TO INNOVATIVE MEDICINAL PRODUCTS, BLURRING THE TRUE PICTURE ABOUT THE SAFETY AND EFFECTIVENESS OF SUCH PRODUCTS WHEN USED BY THESE COMMUNITIES, AND HINDERING THE ACCEPTABILITY AND UPTAKE OF SUCH PRODUCTS BY MEMBERS OF ETHNIC MINORITIES. ULTIMATELY, THIS LEADS TO MAJOR DISPARITIES AND WORSE HEALTH OUTCOMES. PLHB AND ETHNIC MINORITIES WERE UNDERREPRESENTED IN CLINICAL TRIALS FOR THE VACCINE AGAINST SARS-COV-2 (COVID-19). THIS HAS LED PLHB TO BE CONCERNED ABOUT HOW THE VACCINE WOULD AFFECT THEIR LIVER OR HEALTH CONDITION AND HAS EXPOSED AN EXISTING GAP OF LACK OF DIALOGUE BETWEEN DRUG DEVELOPERS AND COMMUNITY ORGANIZATIONS REPRESENTING PLHB AND ETHNIC MINORITIES. THE PROPOSED STUDY WILL HELP BETTER UNDERSTAND THE CHALLENGES AND RESULTING HEALTH BEHAVIORS (INCLUDING COVID-19 VACCINE UPTAKE) AMONG INDIVIDUALS FROM MINORITY POPULATIONS, INCLUDING PLHB, INCLUDING AN ASSESSMENT OF THEIR ACCESS TO CREDIBLE AND PATIENT-CENTERED INFORMATION ON THE SAFETY OF COVID-19 VACCINES. THE STUDY PROPOSES A MIXED-METHODS APPROACH, COLLECTING AND ANALYZING DATA FROM PLHB AND ETHNIC MINORITIES, AND THEIR HEALTHCARE PROVIDERS, THROUGH ONE-ON-ONE INTERVIEWS AND AN ONLINE SURVEY. THE STUDY ALSO PROPOSES ESTABLISHING AN INFORMED COMMUNITY ADVISORY BOARD (CAB) COMPOSED OF PLHB WHO REPRESENT ETHNIC POPULATIONS MOST IMPACTED BY CHB. CAB MEMBERS WILL BE TRAINED ON TOPICS RELATED TO COVID-19, PUBLIC HEALTH EMERGENCIES, AND CLINICAL TRIAL PARTICIPATION. CAB MEMBERS WILL CULTIVATE A SUSTAINABLE DIALOGUE WITH THE DRUG DEVELOPMENT COMMUNITY, SUCH AS REGULATORY AUTHORITIES AND DRUG DEVELOPERS, ESPECIALLY DURING TIMES OF PUBLIC HEALTH EMERGENCIES. THIS STUDY WILL BROADEN OUR UNDERSTANDING OF HOW ETHNIC MINORITIES PERCEIVE NEWLY APPROVED MEDICINAL PRODUCTS, AND IDEAS FOR IMPROVING FUTURE COMMUNICATION ABOUT THESE PRODUCTS. STUDY RESULTS CAN BE USED TO PROMOTE DIVERSITY AND INCLUSION IN CLINICAL TRIALS FOR COVID-19 VACCINES AND THERAPEUTICS AND NEWLY DEVELOPED PRODUCTS IN OTHER DISEASE AREAS, AND ENSURE THAT THE BENEFITS OF SUCH TRIALS REACH THE COMMUNITIES MOST IN NEED, IN THE U.S. AND GLOBALLY.

COMMUNITY PROJECT FUNDING/CONGRESSIONALLY DIRECTED SPENDING - NON-CONSTRUCTION

2009 MOLECULAR BIOLOGY OF HEPATITIS B VIRUSES MEETING

2011 INTERNATIONAL MEETING ON THE MOLECULAR BIOLOGY OF HEPATITIS B VIRUSES

2010 MOLECULAR BIOLOGY OF HEPATITIS B VIRUSES MEETING

2008 INTERNATIONAL MEETING: THE MOLECULAR BIOLOGY OF HEPATITIS B VIRUSES

2013 INTERNATIONAL MEETING ON THE MOLECULAR BIOLOGY OF HEPATITIS B VIRUSES

2023 INTERNATIONAL HBV MEETING - ABSTRACT/SUMMARY HEPATITIS B VIRUS (HBV) IS A MAJOR GLOBAL PUBLIC HEALTH THREAT WITH APPROXIMATELY 296 MILLION CHRONICALLY INFECTED PEOPLE WORLDWIDE AND OVER 800,000 DEATHS PER YEAR. CHRONIC HBV INFECTION IS A LEADING CAUSE FOR DEVELOPMENT OF LIVER CIRRHOSIS AND HEPATOCELLULAR CARCINOMA. DESPITE THE EFFECTIVENESS OF THE PROPHYLACTIC HBV VACCINE, IT HAS NO IMPACT ON ESTABLISHED CHRONIC INFECTIONS. CONSEQUENTLY, THERE IS A GREAT NEED TO DISCOVER NEW THERAPEUTIC STRATEGIES TO CURE CHRONIC HBV INFECTION AND SLOW OR STOP THE RESULTING DISEASE. THE ANNUAL INTERNATIONAL HBV MEETING IS THE ONLY FORUM THAT GATHERS THE INTERNATIONAL COMMUNITY OF RESEARCHERS WHO STUDY INFECTION, PERSISTENCE, PATHOGENESIS, AND DRUG DEVELOPMENT FOR HBV AND THE CLOSELY ASSOCIATED HEPATITIS DELTA VIRUS (HDV). THIS INTERNATIONAL HBV MEETING HAS BEEN HELD YEARLY SINCE 1985. IN 2023, THIS MEETING WILL BE HELD FOR THE FIRST TIME IN JAPAN, IN EAST ASIA WHERE CHRONIC HEPATITIS B IS HIGHLY ENDEMIC, WITH OVER 100 MILLION PEOPLE CHRONICALLY AFFECTED. SUCCESS OF THE INTERNATIONAL HBV MEETING RELIES ON THE CONTRIBUTIONS OF NOT ONLY THE ESTABLISHED INVESTIGATORS, BUT IMPORTANTLY, ALSO ON EARLY CAREER RESEARCHERS FROM DIVERSE BACKGROUNDS. TO FACILITATE THE PARTICIPATION OF YOUNG SCIENTISTS, WE REQUEST FUNDING TO SUPPORT TRAVEL EXPENSES FOR EARLY CAREER AND UNDER- REPRESENTED RESEARCHERS AT THE 2023 INTERNATIONAL HBV MEETING. THIS 2023 MEETING WILL PROVIDE THE OPPORTUNITY FOR SCIENTIFIC EXCHANGE AND DISSEMINATION OF THE LATEST RESEARCH INFORMATION TO DISCOVER NEW STRATEGIES FOR POTENTIALLY CURING HBV AND HDV. AN ESTIMATED 500-600 DELEGATES WILL ATTEND THE 2023 MEETING. THE MEETING WILL CONSIST OF 10 ORAL SCIENTIFIC SESSIONS, 2 POSTER SESSIONS, 3 PLENARY LECTURES FROM EXPERTS OUTSIDE OF THE HBV FIELD WHO WILL BRING DIFFERENT PERSPECTIVES, AND A LECTURE GIVEN BY THE RECIPIENT OF THE DISTINGUISHED AWARD IN HBV RESEARCH THAT IS AWARDED ANNUALLY BY THE MEETING. TOWARD THE GOAL OF CURING HBV AND HDV, THIS MEETING WILL BE SATELLITED BY HBV CURE SYMPOSIUM TO DISCUSS MECHANISMS UNDERLYING DURABILITY OF ANTI-HBV SIRNA THERAPY, AND BY AN HBV COMMUNITY FORUM WHERE SCIENTISTS FROM THE HBV COMMUNITY ENGAGE WITH THE GENERAL PUBLIC, MEDIA, STUDENTS AND THOSE AFFECTED BY HBV TO DISCUSS HBV/HDV AND THE RELATED DISEASES. AS IN THE PAST, GREAT EFFORT HAS BEEN MADE TO MINIMIZE THE COST OF THE MEETING. A MAJOR STRENGTH OF THE MEETING ORGANIZATION BEING CONTINUAL SUPPORT FROM THE HEPATITIS B FOUNDATION SINCE 2005. IN ORDER TO ENABLE AND FACILITATE PARTICIPATION OF EARLY CAREER RESEARCHERS AND UNDER-REPRESENTED MINORITY INVESTIGATORS TO MAXIMIZE THE SIGNIFICANCE OF THE MEETING, WE REQUEST SUPPORT FROM THE NATIONAL INSTITUTES OF HEALTH TO HELP DEFRAY THEIR TRAVEL COSTS. THIS FUNDING WILL BE USED TO ENSURE ATTENDANCE AND PRESENTATION BY EARLY CAREER RESEARCHERS, PARTICULARLY FROM LOW AND MIDDLE-INCOME COUNTRIES, AS WELL AS DISADVANTAGED AND UNDER-REPRESENTED MINORITY INVESTIGATORS.

2019 INTERNATIONAL MEETING ON THE MOLECULAR BIOLOGY OF HEPATITIS B VIRUSES

2017 INTERNATIONAL MEETING ON THE MOLECULAR BIOLOGY OF HEPATITIS B VIRUSES

2018 INTERNATIONAL MEETING ON THE MOLECULAR BIOLOGY OF HEPATITIS B VIRUSES

2014 INTERNATIONAL MEETING ON THE MOLECULAR BIOLOGY OF HEPATITIS B VIRUSES

2024 INTERNATIONAL MEETING ON THE MOLECULAR BIOLOGY OF HEPATITIS B VIRUSES (INTERNATIONAL HBV MEETING) - ABSTRACT/SUMMARY HEPATITIS B VIRUS (HBV) IS A MAJOR GLOBAL PUBLIC HEALTH THREAT WITH APPROXIMATELY 296 MILLION CHRONICALLY INFECTED PEOPLE WORLDWIDE AND OVER 800,000 DEATHS PER YEAR. CHRONIC HBV INFECTION IS A LEADING CAUSE FOR DEVELOPMENT OF LIVER CIRRHOSIS AND HEPATOCELLULAR CARCINOMA. DESPITE THE EFFECTIVENESS OF THE PROPHYLACTIC HBV VACCINE, IT HAS NO IMPACT ON ESTABLISHED CHRONIC INFECTIONS. CONSEQUENTLY, THERE IS A GREAT NEED TO DISCOVER NEW THERAPEUTIC STRATEGIES TO CURE CHRONIC HBV INFECTION AND SLOW OR STOP THE RESULTING DISEASE. THE ANNUAL INTERNATIONAL HBV MEETING IS THE ONLY FORUM THAT GATHERS THE INTERNATIONAL COMMUNITY OF RESEARCHERS WHO STUDY INFECTION, PERSISTENCE, PATHOGENESIS, AND DRUG DEVELOPMENT FOR HBV AND THE CLOSELY ASSOCIATED HEPATITIS DELTA VIRUS (HDV). THIS INTERNATIONAL HBV MEETING HAS BEEN HELD YEARLY SINCE 1985 AND HAS BEEN ROTATING BETWEEN THE US, EUROPE, EAST ASIA AND AUSTRALIA. IN 2024, THIS MEETING WILL BE HELD CHICAGO, IL, IN 2025 IN EUROPE AND THE MEETING SITE FOR 2026 WILL BE DETERMINED NEXT YEAR. SUCCESS OF THE INTERNATIONAL HBV MEETING RELIES ON THE CONTRIBUTIONS OF NOT ONLY THE ESTABLISHED INVESTIGATORS, BUT IMPORTANTLY, ALSO ON EARLY CAREER RESEARCHERS FROM DIVERSE BACKGROUNDS. TO FACILITATE THE PARTICIPATION OF YOUNG SCIENTISTS, WE REQUEST FUNDING TO SUPPORT TRAVEL EXPENSES FOR EARLY CAREER AND UNDER- REPRESENTED RESEARCHERS AT THE 2024, 2025 AND 2026 INTERNATIONAL HBV MEETINGS. THE 2024 MEETING WILL PROVIDE THE OPPORTUNITY FOR SCIENTIFIC EXCHANGE AND DISSEMINATION OF THE LATEST RESEARCH INFORMATION TO DISCOVER NEW STRATEGIES FOR POTENTIALLY CURING HBV AND HDV. AN ESTIMATED 500-600 DELEGATES WILL ATTEND THE 2024 MEETING. THE MEETING WILL CONSIST OF 10 ORAL SCIENTIFIC SESSIONS, 2 POSTER SESSIONS, 3 PLENARY LECTURES FROM EXPERTS OUTSIDE OF THE HBV FIELD WHO WILL BRING DIFFERENT PERSPECTIVES, AND A LECTURE GIVEN BY THE RECIPIENT OF THE DISTINGUISHED AWARD IN HBV RESEARCH THAT IS AWARDED ANNUALLY BY THE MEETING. TOWARD THE GOAL OF CURING HBV AND HDV, THIS MEETING WILL HOST A HBV CURE SATELLITE SYMPOSIUM TO DISCUSS MECHANISMS OF ANTIVIRAL THERAPIES, AND BY AN HBV COMMUNITY FORUM WHERE SCIENTISTS FROM THE HBV COMMUNITY ENGAGE WITH THE GENERAL PUBLIC, MEDIA, STUDENTS AND THOSE AFFECTED BY HBV TO DISCUSS HBV/HDV AND THE RELATED DISEASES. AS IN THE PAST, GREAT EFFORT HAS BEEN MADE TO MINIMIZE THE COST OF THE MEETING. A MAJOR STRENGTH OF THE MEETING ORGANIZATION BEING CONTINUAL SUPPORT FROM THE HEPATITIS B FOUNDATION SINCE 2005. TO ENABLE AND FACILITATE PARTICIPATION OF EARLY CAREER RESEARCHERS AND UNDER-REPRESENTED MINORITY INVESTIGATORS TO MAXIMIZE THE SIGNIFICANCE OF THE MEETING, WE REQUEST SUPPORT FROM THE NATIONAL INSTITUTES OF HEALTH TO HELP DEFRAY THEIR TRAVEL COSTS. THIS FUNDING WILL BE USED TO ENSURE ATTENDANCE AND PRESENTATION BY EARLY CAREER RESEARCHERS, PARTICULARLY FROM LOW AND MIDDLE-INCOME COUNTRIES, AS WELL AS DISADVANTAGED AND UNDER-REPRESENTED MINORITY INVESTIGATORS.

2015 INTERNATIONAL MEETING ON THE MOLECULAR BIOLOGY OF HEPATITIS B VIRUSES

2012 INTERNATIONAL MEETING ON THE MOLECULAR BIOLOGY OF HEPATITIS B VIRUSES

2020 INTERNATIONAL MEETING ON THE MOLECULAR BIOLOGY OF HEPATITIS B VIRUSES - ABSTRACT/SUMMARY HEPATITIS B VIRUS (HBV) INFECTION IS A SIGNIFICANT GLOBAL PUBLIC HEALTH PROBLEM, WITH OVER 290 MILLION PEOPLE WORLDWIDE BEING CHRONICALLY INFECTED. SIGNIFICANTLY, CHRONIC HBV INFECTION IS ASSOCIATED WITH INCREASED RISK FOR DEVELOPMENT OF HEPATOCELLULAR CARCINOMA (HCC), THE 2ND LEADING CAUSE OF CANCER-RELATED MORTALITY WORLDWIDE. DESPITE THE EFFECTIVENESS OF THE PROPHYLACTIC HBV VACCINE, THERE IS NO CURE FOR CHRONIC HBV INFECTION OR THE RESULTANT LIVER CANCER. THERE IS COMPELLING NEED TO DISCOVER NEW THERAPEUTIC STRATEGIES TO CURE CHRONIC HBV INFECTION AND HCC PATHOGENESIS. THUS, THE GLOBAL HBV SCIENTIFIC COMMUNITY MUST CONTINUE TO MAKE DIRECTED STRIDES TOWARDS UNDERSTANDING KEY, UNANSWERED ASPECTS OF HBV BIOSYNTHESIS AND DISEASE PATHOGENESIS. THE ANNUAL MEETING ON THE MOLECULAR BIOLOGY OF HEPATITIS B VIRUSES IS THE ONLY FORUM THAT BRINGS TOGETHER THE INTERNATIONAL COMMUNITY OF SCIENTISTS WHO STUDY MECHANISMS OF BIOSYNTHESIS AND PATHOGENESIS BY HBV AND AND ITS CLOSELY ASSOCIATED HEPATITIS DELTA VIRUS (HDV). THIS INTERNATIONAL MEETING ON HEPATITIS B VIRUSES HAS BEEN HELD YEARLY SINCE 1985, ALTERNATING AT SITES IN NORTH AMERICA, EUROPE, ASIA AND AUSTRALIA. IN 2020, THE MEETING WILL BE HELD IN TORONTO, CANADA. THE SUCCESS AND ACHIEVEMENTS OF THE HBV FIELD RELIES ON THE CONTRIBUTIONS OF NOT ONLY THE ESTABLISHED INVESTIGATORS BUT MORE IMPORTANTLY, ON EARLY CAREER RESEARCHERS (ECRS) THAT HAVE/ARE DECIDING TO ENTER THE FIELD, BRINGING WITH THEM NEW TECHNOLOGY AND CONCEPTS. ACCORDINGLY, THE SPECIFIC AIM OF THIS R13 APPLICATION IS: TO PROMOTE AND MAXIMIZE ATTENDANCE AND PARTICIPATION OF EARLY CAREER RESEARCHERS/ECRS (GRADUATE STUDENTS & POSTDOCTORAL FELLOWS) AT THE 2020 INTERNATIONAL HBV MEETING. THE 2020 MEETING WILL PROVIDE THE STAGE FOR SCIENTIFIC EXCHANGE AND DISSEMINATION OF THE LATEST RESEARCH RESULTS THAT COULD INFLUENCE NEW THERAPEUTIC STRATEGIES FOR HBV AND HDV INFECTIONS. IT IS ESTIMATED THAT 500-600 DELEGATES WILL ATTEND THE 2020 MEETING. THE ORGANIZATION OF THE MEETING WILL CONSIST OF 8 ORAL SCIENTIFIC SESSIONS AND 5 POSTER SESSIONS INCLUDING FOR THE FIRST TIME, E-POSTER PRESENTATIONS, AS A TRAINING STAGE FOR EARLY CAREER SCIENTISTS. IN SUPPORT OF THE GOAL OF THE GLOBAL SCIENTIFIC STRATEGY TO CURE HBV, KEYNOTE SPEAKERS WILL PRESENT NEW PERSPECTIVES AND TECHNOLOGIES, AND DISCUSS STANDARDS THAT CAN BE APPLIED TO ADVANCE THE HBV FIELD. TO IMPROVE SCIENTIFIC INTERACTIONS AND SCIENTIFIC EXCHANGE, SOCIAL GATHERINGS ARE ORGANIZED AT THE END OF EACH MEETING DAY. SIGNIFICANTLY, SINCE 2005, THE INTERNATIONAL HBV MEETING ENJOYS THE CONTINUING SUPPORT FROM THE HEPATITIS B FOUNDATION, MINIMIZING THE MEETING COSTS, AND PUBLICIZING THE MEETING TO UNIVERSITIES WITH LARGE NUMBERS OF UNDERREPRESENTED MINORITIES. TO ENABLE PARTICIPATION OF EARLY CAREER TRAINEES AND UNDERREPRESENTED MINORITY INVESTIGATORS, SUPPORT FROM THE NATIONAL INSTITUTES OF HEALTH TO HELP DEFRAY THE TRAVEL COSTS IS REQUESTED. THIS FUNDING WILL BE USED TO ENSURE ATTENDANCE AND PRESENTATIONS BY EARLY CAREER RESEARCHERS, PARTICULARLY FROM COUNTRIES WITH LESSER DEVELOPED RESEARCH CAPACITY, AS WELL AS UNDERREPRESENTED MINORITY INVESTIGATORS.

2016 INTERNATINAL MEETING O THE MOLECULAR BIOLOGY OF HEPATITIS B VIRUSES

HEP B UNITED: NETWORKING, CAPACITY BLDG & TRNG